Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations
Background: This Phase 1b/2 study assessed the efficacy in terms of objective response rate (ORR) of the FGFR1/2/3 kinase inhibitor derazantinib as monotherapy or in combination with atezolizumab in patients with metastatic urothelial cancer ( …